250,66 me sale a mí cierre gap ibb
CERU
plata o plomo
al cierre resultados 0.70 0.73 hoy, perdida toda la subida (after 1.4x)tras noticia colaboración novartis.
compras insiders a 1.0x si no recuerdo mal, pero para mí es como hacerle a un muerto un servicio con pulseras incluidas, o que una farma tenga 90% de institucionales, vamos que no es el caso, 30% creo recordar.
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11640073&RcvdDate=10/19/2016&CoName=CERULEAN%20PHARMA%20INC.&FormType=8-K&View=HTML
The Company is entitled to receive a $5 million upfront payment under the Collaboration Agreement, as well as funding from Novartis for up to five full-time employees of the Company to be engaged in activities under the collaboration during the research term.
Under the Collaboration Agreement, Novartis has the exclusive right to develop, manufacture and commercialize Novartis NDCs for the Designated Targets (the “Commercial Licenses”), provided that Novartis is required to pay to the Company a fee of $7 million with respect to each Designated Target (the “Commercial License Fee”) prior to commencing human clinical trials in that Program. Each Commercial License terminates upon the expiration of the research term with respect to that Program, unless Novartis has either by such time paid to the Company the Commercial License Fee with respect thereto or it pays to the Company an annual maintenance fee that is less than a million dollars per year for the relevant Designated Target, which will extend the period during which Novartis may elect to pay the Commercial License Fee with respect to the Designated Target. For each Designated Target with respect to which Novartis has paid the Company a Commercial License Fee, Novartis will have an obligation to use commercially reasonable efforts to develop and commercialize a Novartis NDC in the United States and Europe.
With respect to each Program, the Company is entitled to receive up to an additional $41.5 million in milestone payments based upon achievement of specified preclinical, development and regulatory milestones, and up to an additional $185 million in milestone payments based upon achievement of specified sales milestones. Including the Commercial License Fee for each Program, the Company may receive up to $233.5 million for each Program, and up to $1.17 billion for all five Programs. The Company is also eligible to receive royalties on net sales of Novartis NDCs, which are tiered based on sales levels and range from single digit to low double-digit percentage rates. Novartis’ obligation to pay milestones is on a product-by-product and country-by-country basis, and will continue with respect to a particular Novartis NDC and country until the later of the date of expiration of the last valid patent claim covering the Novartis NDC in that country, or ten years from the date of the first commercial sale of the Novartis NDC in that country, with such royalties subject to reduction for periods following loss of patent coverage or market exclusivity in that country.